Oluyemi Okupe

CFO Oluyemi Okupe sold 18.2K shares of HIMS at $34.03 under 10b5-1 plan; holds 284.3K shares post-trade plus 109,524 options.

Oluyemi Okupe, CFO of Hims & Hers Health, Inc., sold 18,197 shares at $34.03 on 2026-06-22 as part of a pre-arranged 10b5-1 trading plan adopted on 2025-05-21, reducing his non-derivative holdings by 6.0% to 284,321 shares while retaining 109,524 shares in stock options. The transaction is scheduled rather than discretionary. His prior sales at this ticker show mixed outcomes: the 30-day change following this filing's scheduled execution occurs during a period when HIMS has gained 38.8% over the last 30 days, though the stock remains 53.2% below its 52-week high of $70.43. The company's latest quarter shows $608,104,000 in revenue and a net loss of $92,115,000, with annual revenue growth of +59.0% year-over-year, indicating growth amid current unprofitability.

CFO Okupe Oluyemi sells 19,645 shares of HIMS at $29.96 on 2026-04-20; stock now $29.01, -56.2% from 52-week high.

Okupe Oluyemi, CFO of Hims & Hers, sold 19,645 shares for $588,615.28 on 2026-04-20 at $29.96, reducing holdings by 7.0% to 262,954 shares. This is the third consecutive sale within four calendar days (after sales on 2026-04-17 and 2026-04-16), a compressed selling pattern that differs from his historical cadence. At his same-ticker history, all three prior measurable sells preceded significant declines—his 2025-12-22 sale saw -38.4% 90-day return, 2025-11-17 saw -55.7%, and 2025-10-17 saw -45.3%—establishing a 100% well-timed rate at HIMS specifically. His cross-ticker track record shows 20 prior sells with a 66.67% well-timed rate and average 90-day return of -4.9%, indicating a consistent pattern of selling ahead of downturns. The stock is currently trading -56.2% from its 52-week high of $66.18, though it rose +29.2% in the last 30 days, suggesting recent momentum has not deterred selling by the CFO despite fundamentally strong metrics (annual revenue growth of +59.0%, $599.0M latest quarterly revenue).

CFO Okupe Oluyemi sold 54,927 shares of HIMS for $1,457,305.25 across 2 transactions; 4 of 4 prior HIMS sales were well-timed 90d declines.

Okupe Oluyemi, CFO of Hims & Hers Health, Inc., executed 2 separate sales totaling 54,927 shares for $1,457,305.25 on April 16–17, 2026, at an average blended price of $26.53, reducing his holdings by 16.9% to 270,046 shares post-transaction. His prior trade history at HIMS is notably predictive: 4 of 4 prior sells at this ticker were well-timed at the 90-day mark, with post-sale declines ranging from 38.4% to 55.7%. The stock is currently trading at $31.01, up 40.8% over the past 30 days from the sale dates but down 53.1% from its 52-week high of $66.18, suggesting the April sales occurred near a local high. The company shows strong revenue growth of 59.0% year-over-year ($599.0M latest quarter revenue, $15.8M net income), but the elevated P/E of 54.40 and the CFO's consistent pattern of well-timed exits at this ticker merit attention as a potential signal of valuation concern relative to near-term operational outlook.

CFO Okupe Oluyemi sells 23,090 HIMS shares at $35.72, retaining 94,333 shares; stock down 49.4% from 52-week high.

Oluyemi sold 23,090 shares on 2025-12-22 at $35.72, reducing holdings by 19.7% to 94,333 shares post-transaction, as HIMS trades 49.4% below its 52-week high of $68.74 and down 34.6% over the past 90 days. His five prior sales at HIMS show mixed timing: the 2025-09-22 sale yielded a -38.4% 90-day return (well-timed), but the four more recent sales in October, November, and December occurred as the stock continued declining. His cross-ticker track record shows a 43.75% well-timed sell rate across 20 prior transactions, with a +20.8% average 90-day return, meaning his prior sells tended to precede stock rallies rather than declines. The December sale occurs while HIMS maintains strong fundamentals—$599.0M quarterly revenue with +69.3% annual growth and $15.8M net income—but trades at a 60.0 P/E multiple in a stock down substantially from peak.

HIMS CFO sells 23.2K shares at $36.81; stock now $35.83, down 47.9% from 52-week high. Five consecutive sales in recent weeks.

Okupe Oluyemi sold 23,187 shares at $36.81 on 2025-11-17, reducing his holdings by -24.8% to 70,232 shares post-transaction. The stock has declined significantly: it is currently $35.83 (down 47.9% from the 52-week high of $68.74) and down 30.2% in the past 30 days. His cross-ticker track record shows a 90d well-timed rate of 23.08%, but at HIMS specifically, his four prior measurable sales over the past two months all produced negative 30-day returns (ranging from -17.8% to -35.3%), with the timing pattern at 0 of 0 well-timed at the 90-day mark. This represents his fifth discretionary sale within a six-week window, occurring as the stock enters its most recent steep decline. The frequency and concentration of these open-market sales during a period of acute price deterioration merit scrutiny, particularly given the company's strong revenue growth of +69.3% and recent profitable quarter ($15.8M net income).

CFO Oluyemi sold 11,592 shares of HIMS at $57.13; stock now at $51.36, -25.3% from 52-week high.

CFO Okupe Oluyemi sold 11,592 shares at $57.13 on 2025-10-17, reducing his holdings by 14.2% to 70,232 shares. The stock is currently trading at $51.36, down 11.2% over the prior 30 days and 25.3% below the 52-week high of $68.74, suggesting the sale occurred before a significant drawdown. However, this sale pattern requires context: Oluyemi executed five separate transactions at HIMS over the prior three weeks (2025-09-15 through 2025-10-17), with two recent trades yet to show measurable 30-day returns. His cross-ticker track record shows 20 prior sells with a 15.38% well-timed rate, though none of his prior HIMS sales have yet registered a well-timed outcome at the 90-day mark (0 of 0). Notably, HIMS fundamentals remain strong with $544.8M quarterly revenue, +69.3% annual growth, and $42.5M net income, though the P/E of 88.55 reflects elevated valuation. The repeated sales within a compressed timeframe merit observation against the company's growth metrics.

CFO Okupe Oluyemi sold 11,595 shares of HIMS at $57.72 on 2025-10-03, reducing holdings by 14.2%.

CFO Okupe Oluyemi executed a sale of 11,595 shares at $57.72 on 2025-10-03, reducing his position from 81,827 shares to 70,232 shares. The timing context is notable: HIMS has appreciated +19.8% over the prior 30 days and +13.1% over 90 days, yet trades at $57.97 currently—15.7% below its 52-week high of $68.74. The SAME-TICKER HISTORY reveals a concentrated selling pattern: four sales between 2025-08-26 and 2025-09-29 immediately prior to this transaction, with only one measurable outcome (30d: +25.6% from the 2025-08-26 sale). His cross-ticker track record shows avg 90d returns of +47.0% after sells with a 15.38% well-timed rate, suggesting his prior sells have generally preceded stock gains rather than declines. Against strong near-term momentum and a portfolio of fundamentals showing +69.3% annual revenue growth and positive net income of $42,505,000.00, the series of incremental sales warrants attention to whether this reflects deliberate portfolio management or a shift in conviction toward the position.

CFO Okupe Oluyemi sold 85,000 HIMS shares at $60.20 (9/29), reducing stake by 54.8%; recent rapid series (5 trades in ~6 weeks, 3 in same week)

Okupe Oluyemi, the CFO of Hims & Hers Health, sold 85,000 shares valued at $5,116,923.50 at $60.20, cutting his holdings from 155,232 to 70,232 shares—a 54.8% reduction. The timing and pattern raise questions: this is the fifth HIMS trade in approximately six weeks, including three separate sales on 2025-09-15 alone and another on 2025-09-22. The sale occurred near the stock's 52-week high of $68.74, though the current price of $56.72 suggests the stock has already declined 17.5% from peak. Across his cross-ticker history, Oluyemi's sell trades have generated an average 90-day return of +48.1% (meaning stock tends to rise post-sale), reflecting a 15.38% well-timed rate on the downside; however, at HIMS specifically, he has no measurable 90-day outcomes yet, so prior HIMS timing patterns cannot be evaluated. The concentrated selling pattern and significant position reduction merit scrutiny into whether operational or strategic conditions are driving the sustained liquidation.

CFO Okupe Oluyemi sold 23.6K HIMS shares at $57.74; stock now -22.5% from 52-week high at $53.25

CFO Okupe Oluyemi sold 23,584 shares at $57.74 on 2025-09-22, reducing holdings by -18.3% from 129.0K to 105.4K shares, for a total value of $1,361,766.10. The sale occurred near a recent intra-period peak: the stock has since fallen to $53.25, down -22.5% from its 52-week high of $68.74, though it remains +23.9% higher over the past 30 days. At the cross-ticker level, Okupe's 20 prior sells across all holdings show a well-timed rate of 14.29%, suggesting mixed timing; however, at HIMS specifically, his 5 prior trades show 0 well-timed outcomes at the 90-day mark. The company reports strong fundamentals with $544.8M revenue (+69.3% annual growth) and $42.5M net income, though the elevated P/E of 91.81 reflects high valuation expectations. This sale follows two other HIMS sales on 2025-09-15 and comes amid ongoing stock strength, warranting monitoring of whether this marks a pattern of management liquidity or a signal of valuation concerns.

HIMS CFO Okupe Oluyemi sold 145,000 shares (52.9% of holdings) for $8,026,075.61 on 2025-09-15

On 2025-09-15, Chief Financial Officer Okupe Oluyemi executed 2 separate sales totaling 145,000 shares for $8,026,075.61 at a blended average price of $55.35, reducing his holdings from 273,984 to 128,984 shares—a 52.9% reduction of his pre-transaction position. The sale occurred near the 52-week high range (current price $50.35 is 26.8% below the $68.74 52-week high), and at the time of sale the stock had appreciated 11.6% over the prior 30 days. His prior 5 trades at HIMS have shown positive 30-day returns (ranging from +1.3% to +22.8%), but measurable 90-day outcomes remain unavailable. Across his broader cross-ticker history, his 20 prior sells averaged +9.8% 30-day and +45.0% 90-day returns, with a 13.33% well-timed rate, suggesting his prior open-market sales have historically underperformed subsequent stock appreciation. The magnitude of this position reduction—removing 52.9% of holdings in a single filing—represents a significant capital redeployment by a senior finance officer at a company with 69.3% annual revenue growth and a P/E of 86.81.